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High circulating levels of apoA-I are associated with a reduced risk of coronary heart disease (CHD). ApoA-I transports cholesterol away from 
peripheral tissues and this action is thought to underlie the inverse correlation of apoA-I levels with CHD. Based on these observations, several 
groups have manufactured apoA-I preparations with the aim of making an infused HDL therapy for the acute treatment of atherosclerotic lesions in 
humans. We have recently described a new formulation of full length apoA-I (CSL112) that can be produced on a commercial scale and that was 
optimized to interact with ATP-binding cassette transporter A1 (ABCA1). A key step in transport of cholesterol from the periphery is esterification by 
LCAT to enable greater carrying capacity. Here we show that the in vitro addition of CSL112 to human plasma dose-dependently increased the rate 
of cholesterol esterification catalyzed by LCAT. In vivo, the infusion of CSL112 into rabbits caused a long-lasting 2-fold activation of endogenous LCAT. 
In monkeys, infusion of CSL112 resulted in an immediate increase in plasma free cholesterol followed by a concomitant decline in free cholesterol 
and accumulation of cholesteryl ester. These data suggest ongoing LCAT action in response to infusion of CSL112. We conclude that CSL112 rapidly 
and effectively promotes not only initial cholesterol efflux from cells but also the next step of reverse cholesterol transport, esterification of free 
cholesterol. CSL112 may thus provide a novel option for rapid reduction of systemic atherosclerotic burden.
